Healthcare provider profile · identity verified

William B Richardson, MD

Allopathic & Osteopathic Physicians|Family Medicine · EASTPORT, ME · NPI 1457409617

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show William B Richardson, MD received $64.34 in general payments during 2025 across 3 reported records.

ABBVIE INC. accounted for 50.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$64.34

3 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$32.44	50.4%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$31.90	49.6%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$64.34	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$32.44	1	2025
Source payment records 2025-09-04 · ABBVIE INC. · $32.44 · Open Payments source
BREZTRI Normalized: breztri	Drug	AstraZeneca Pharmaceuticals LP	$31.90	2	2025
Source payment records 2025-05-28 · AstraZeneca Pharmaceuticals LP · $16.71 · Open Payments source 2025-09-30 · AstraZeneca Pharmaceuticals LP · $15.19 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	727	78
Eliquis	Apixaban	707	60
Quetiapine Fumarate	Quetiapine Fumarate	548	45
Atorvastatin Calcium	Atorvastatin Calcium	538	81
Escitalopram Oxalate	Escitalopram Oxalate	537	29
Sertraline Hcl	Sertraline Hcl	408	37
Pantoprazole Sodium	Pantoprazole Sodium	393	37
Amlodipine Besylate	Amlodipine Besylate	385	65
Trazodone Hcl	Trazodone Hcl	369	35
Metoprolol Succinate	Metoprolol Succinate	361	39
Buspirone Hcl	Buspirone Hcl	360	26
Furosemide	Furosemide	351	58
Lisinopril	Lisinopril	345	32
Divalproex Sodium	Divalproex Sodium	343	31
Gabapentin	Gabapentin	308	55
Famotidine	Famotidine	304	16
Clopidogrel	Clopidogrel Bisulfate	284	22
Donepezil Hcl	Donepezil Hcl	267	18
Losartan Potassium	Losartan Potassium	237	17
Mirtazapine	Mirtazapine	232	26
Olanzapine	Olanzapine	220	17
Carvedilol	Carvedilol	216	14
Torsemide	Torsemide	205	24
Tamsulosin Hcl	Tamsulosin Hcl	203	30
Xarelto	Rivaroxaban	202	16
Memantine Hcl	Memantine Hcl	174	11
Potassium Chloride	Potassium Chloride	171	32
Metoprolol Tartrate	Metoprolol Tartrate	166	42
Levetiracetam	Levetiracetam	164	27
Omeprazole	Omeprazole	156	15
Spironolactone	Spironolactone	151	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	130	18
Metformin Hcl	Metformin Hcl	121	16
Metformin Hcl Er	Metformin Hcl	121	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	117	13
Aripiprazole	Aripiprazole	115	suppressed
Risperidone	Risperidone	112	21
Topiramate	Topiramate	109	suppressed
Allopurinol	Allopurinol	107	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	105	suppressed
Prednisone	Prednisone	104	42
Trulicity	Dulaglutide	103	11
Xofluza	Baloxavir Marboxil	103	101
Citalopram Hbr	Citalopram Hydrobromide	95	suppressed
Finasteride	Finasteride	89	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	86	55
Tramadol Hcl	Tramadol Hcl	86	46
Myrbetriq	Mirabegron	85	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	84	suppressed
Rexulti	Brexpiprazole	84	suppressed
Lidocaine Hcl	Lidocaine Hcl	81	58
Lorazepam	Lorazepam	80	50
Januvia	Sitagliptin Phosphate	79	suppressed
Amiodarone Hcl	Amiodarone Hcl	77	14
Entresto	Sacubitril/Valsartan	77	suppressed
Midodrine Hcl	Midodrine Hcl	77	suppressed
Glimepiride	Glimepiride	75	suppressed
Meloxicam	Meloxicam	75	suppressed
Cephalexin	Cephalexin	74	49
Isosorbide Mononitrate Er	Isosorbide Mononitrate	73	suppressed
Ceftriaxone	Ceftriaxone Sodium	71	53
Doxycycline Hyclate	Doxycycline Hyclate	70	51
Paroxetine Hcl	Paroxetine Hcl	70	suppressed
Warfarin Sodium	Warfarin Sodium	68	suppressed
Baclofen	Baclofen	66	suppressed
Duloxetine Hcl	Duloxetine Hcl	62	12
Oxycodone Hcl	Oxycodone Hcl	61	40
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	56	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	56	suppressed
Irbesartan	Irbesartan	54	suppressed
Labetalol Hcl	Labetalol Hcl	54	suppressed
Hydralazine Hcl	Hydralazine Hcl	52	13
Hydroxyzine Hcl	Hydroxyzine Hcl	52	17
Verapamil Er	Verapamil Hcl	52	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	51	11
Albuterol Sulfate Hfa	Albuterol Sulfate	50	27
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	50	11
Solifenacin Succinate	Solifenacin Succinate	48	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	47	40
Ursodiol	Ursodiol	46	suppressed
Alendronate Sodium	Alendronate Sodium	45	suppressed
Farxiga	Dapagliflozin Propanediol	44	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	42	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	41	suppressed
Ondansetron Hcl	Ondansetron Hcl	41	18
Glipizide Er	Glipizide	40	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	39	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	39	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	38	suppressed
Propranolol Hcl	Propranolol Hcl	38	suppressed
Bupropion Xl	Bupropion Hcl	36	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	35	12
Bumetanide	Bumetanide	34	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	34	22
Clonidine Hcl	Clonidine Hcl	34	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	34	suppressed
Lamotrigine	Lamotrigine	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Hydrocortisone	Hydrocortisone	33	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	33	22
Montelukast Sodium	Montelukast Sodium	33	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	32	suppressed
Digoxin	Digoxin	32	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	18
Lantus	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Valsartan	Valsartan	31	suppressed
Nuplazid	Pimavanserin Tartrate	30	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	29	16
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	29	23
Sodium Chloride	0.9 % Sodium Chloride	28	19
Azithromycin	Azithromycin	27	23
Jardiance	Empagliflozin	27	suppressed
Ondansetron Odt	Ondansetron	27	15
Simvastatin	Simvastatin	26	suppressed
Colchicine	Colchicine	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Ranolazine Er	Ranolazine	25	suppressed
Atenolol	Atenolol	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Daptomycin	Daptomycin	24	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Incruse Ellipta	Umeclidinium Bromide	24	suppressed
Memantine Hcl Er	Memantine Hcl	24	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	24	suppressed
Admelog Solostar	Insulin Lispro	23	suppressed
Novolog Flexpen	Insulin Aspart	23	suppressed
Dilt-Xr	Diltiazem Hcl	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Bupropion Hcl	Bupropion Hcl	21	suppressed
Humalog Kwikpen U-100	Insulin Lispro	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	21	16
Methotrexate	Methotrexate Sodium	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	19	suppressed
Levofloxacin	Levofloxacin	19	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	11
Dapagliflozin	Dapagliflozin Propanediol	18	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	17	suppressed
Latanoprost	Latanoprost	17	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	17	suppressed
Metolazone	Metolazone	17	suppressed
Primidone	Primidone	17	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	17	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Fluticasone Propionate	Fluticasone Propionate	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Linzess	Linaclotide	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Megestrol Acetate	Megestrol Acetate	14	suppressed
Metronidazole	Metronidazole	14	suppressed
Tetrabenazine	Tetrabenazine	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Dimethyl Fumarate	Dimethyl Fumarate	13	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Nystatin	Nystatin	13	suppressed
Ramipril	Ramipril	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	12	suppressed
Ertapenem	Ertapenem Sodium	12	suppressed
Methimazole	Methimazole	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Dutasteride	Dutasteride	11	suppressed
Entacapone	Entacapone	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Konvomep	Omeprazole/Sodium Bicarbonate	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Pulmicort Flexhaler	Budesonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$64.34 · 3 records	ABBVIE INC.	BREZTRI, VRAYLAR	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error